Medical Condition

brain metastases

Total Trials

12

Recruiting Now

12

Trial Phases

Phase 3, Phase 1, Phase 2, Phase 1

ClinicalMetric tracks all active clinical trials for brain metastases sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — brain metastases Clinical Trials

How many clinical trials are currently recruiting for brain metastases?

ClinicalMetric currently tracks 12 actively recruiting clinical trials for brain metastases, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 12. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for brain metastases?

brain metastases research spans Phase 1 (3 trials), Phase 2 (8 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a brain metastases clinical trial?

Eligibility criteria for brain metastases trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Phase 3

Top Sponsors

M.D. Anderson Cancer Center 3 trials

Baptist Health South Florida 2 trials

Institut Cancerologie de l'Ouest 1 trial

Essen Biotech 1 trial

Rongrong Zhou 1 trial

Recruiting Clinical Trials

NCT06471465 Phase 3

Recruiting

Corticodependent or Corticoresistant Brain Radionecrosis After Radiotherapy for Brain Metastases

Institut Cancerologie de l'Oue...

View Trial →

NCT06640582 Phase 1, Phase 2

Recruiting

TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas

Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery

Baptist Health South Florida

View Trial →

NCT06702826 Phase 2

Recruiting

Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases

MeDex: No Perioperative Dexamethasone in Brain Metastases

University of Louisville

View Trial →

NCT06649058 Phase 2

Recruiting

EXCLAIM: Exploring Combined Local and Systemic Approaches In Brain Metastasis: a Multi-cohort Randomized Phase II Study Evaluating Initial Response to Systemic Therapy and Subsequent Integration of Stereotactic Radiosurgery in Patients With Low-risk Brain Metastases and Central Nervous System-active

M.D. Anderson Cancer Center

View Trial →

NCT06822543 Phase 2

Recruiting

A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)

Latin American Cooperative Onc...

View Trial →

NCT04899908 Phase 2

Recruiting

Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

Brigham and Women's Hospital

View Trial →

NCT06048094 Phase 1

Recruiting

18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery

Baptist Health South Florida

View Trial →

NCT05048212 Phase 2

Recruiting

A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases

M.D. Anderson Cancer Center

View Trial →

NCT07462507 Phase 2

Recruiting

Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1

Washington University School o...

View Trial →

NCT05700721 Phase 2

Recruiting

Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)

M.D. Anderson Cancer Center

View Trial →

Related Conditions

brain cancer (4) brain tumor (2) brain metastases adult (2) non small cell lung cancer (2) stereotactic radiation (2) lung cancer (2) radionecrosis of brain (1) glioma (1) gliomas malignant (1) glioblastoma (1) meningioma (1) immunotherapy (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology